Related Experiment Video
Updated: Apr 25, 2026

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
Published on: January 29, 2018
Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma
Alexander Hoellein1, Mohammad Fallahi2, Stephanie Schoeffmann1
1III. Medical Department, Technische Universität München, Munich, Germany;
Abstract:
Myc oncogenic transcription factors (c-Myc, N-Myc, and L-Myc) coordinate the control of cell growth, division, and metabolism. In cancer, Myc overexpression is often associated with aggressive disease, which is in part due to the destruction of select targets by the ubiquitin-proteasome system (eg, SCF(Skp2)-directed destruction of the Cdk inhibitor p27(Kip1)). We reasoned that Myc would also regulate SUMOylation, a related means of posttranslational modification of proteins, and that this circuit would play essential roles in Myc-dependent tumorigenesis. Here, we report marked increases in the expression of genes that encode regulators and components of the SUMOylation machinery in mouse and human Myc-driven lymphomas, resulting in hyper-SUMOylation in these tumors. Further, inhibition of SUMOylation by genetic means disables Myc-induced proliferation, triggering G2/M cell-cycle arrest, polyploidy, and apoptosis. Using genetically defined cell models and conditional expression systems, this response was shown to be Myc specific. Finally, in vivo loss-of-function and pharmacologic studies demonstrated that inhibition of SUMOylation provokes rapid regression of Myc-driven lymphoma. Thus, targeting SUMOylation represents an attractive therapeutic option for lymphomas with MYC involvement.
Insights
Myc overexpression drives aggressive cancers by altering protein modification. Inhibiting SUMOylation, a key process, halts Myc-driven lymphoma growth and triggers tumor regression, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Myc oncogenic transcription factors (c-Myc, N-Myc, L-Myc) regulate cell growth, division, and metabolism.
- Myc overexpression in cancer correlates with aggressive disease, partly via the ubiquitin-proteasome system.
- The role of SUMOylation, a related posttranslational modification, in Myc-driven tumorigenesis was unexplored.
Purpose of the Study:
- To investigate the role of SUMOylation in Myc-dependent tumorigenesis.
- To determine if Myc regulates SUMOylation pathways.
- To explore SUMOylation inhibition as a therapeutic strategy for Myc-driven lymphomas.
Main Methods:
- Analysis of SUMOylation machinery gene expression in mouse and human Myc-driven lymphomas.
- Genetic inhibition of SUMOylation in Myc-driven cancer models.
- In vivo loss-of-function and pharmacologic studies.
Main Results:
- Myc-driven lymphomas exhibit increased expression of SUMOylation regulators, leading to hyper-SUMOylation.
- Inhibition of SUMOylation halts Myc-induced proliferation, causing cell-cycle arrest, polyploidy, and apoptosis.
- Targeting SUMOylation leads to rapid regression of Myc-driven lymphoma in vivo.
Conclusions:
- Myc regulates SUMOylation pathways, contributing to tumorigenesis.
- SUMOylation is essential for Myc-driven lymphoma proliferation and survival.
- Inhibition of SUMOylation is a promising therapeutic approach for lymphomas involving MYC.
More Related Videos
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic...
Abnormal Proliferation
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

